Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss per Share - Basic and Diluted

Net Loss per Share - Basic and Diluted

3 Months Ended

Mar. 31, 2023

Basic and diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding for the time period, which for basic net loss per share, does not include the weighted-average unvested restricted common stock that has been issued and is subject to forfeiture totaling 70,550 and 220 shares for the three months ended March 31, 2023 and 2022, respectively.

Dilutive common equivalent shares consist of stock options, warrants, and preferred stock and are calculated using the treasury stock method, which assumes the repurchase of common shares at the average market price during the period. Under the treasury stock method, options and warrants will have a dilutive effect when the average price of common stock during the period exceeds the exercise price of options or warrants. Common equivalent shares do not qualify as participating securities. In periods where the Company records a net loss unvested restricted common stock and potential common stock equivalents are not included in the calculation of diluted net loss per share as their effect would be anti-dilutive. The following is a summary of potential common shares excluded from the calculation of net loss per share as of March 31:


	2023	2022
Common Stock Warrants	1,653,202	168,932
Employee Stock Options	211,578	16,954
Restricted Stock	70,550	220
Preferred Stock	52	2
Common Stock Reserved for Future Issuance	11,366	—
Total Shares of Common Stock Issuable	1,946,748	186,108